Global Leading Market Research Publisher QYResearch announces the release of its latest report “Automated Biobanking Solution – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Automated Biobanking Solution market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Automated Biobanking Solution was estimated to be worth US$ 4410 million in 2025 and is projected to reach US$ 8898 million, growing at a CAGR of 10.7% from 2026 to 2032. In 2024, global Automated Biobanking Solution production reached approximately 30.649 k set with an average global market price of around US$143,000 per set. An Automated Biobanking Solution is an advanced, integrated system that extends the capabilities of traditional biobanking by incorporating robotics and automation technologies to streamline sample handling, aliquoting, and storage processes. This solution significantly increases throughput, reduces human error, and enhances sample tracking and integrity, all while providing scalability and seamless data integration with LIMS, thereby optimizing the efficiency, reliability, and productivity of biobank operations.
Addressing Core High-Throughput Sample Processing, Cryopreservation Integrity, and LIMS Integration Pain Points
Biobank managers, clinical research laboratories, hospital biorepositories, and pharmaceutical R&D facilities face persistent challenges: manual sample handling (aliquoting, labeling, racking) is slow, error-prone, and limits throughput (50-200 samples/hour). Sample integrity risks (freeze-thaw cycles, temperature excursions) compromise downstream research. Automated biobanking solutions—robotic sample preparation devices, -80°C automated storage systems, liquid nitrogen cryobiology storage, environmental monitoring, and LIMS (Laboratory Information Management Systems)—have emerged as the solution for high-throughput, error-free, traceable biospecimen management. However, product selection is complicated by five distinct system components: sample preparation devices (aliquoters, tube labelers, decappers), cryobiology storage system (-80°C freezers, LN2 dewars, automated storage), cryobiology storage consumables (cryovials, racks, barcodes), environmental monitoring system (temperature, humidity, CO2), and LIMS (sample tracking, chain of custody). Over the past six months, new biopharma R&D investment, personalized medicine biobanking, and AI-powered sample management have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6097634/automated-biobanking-solution
Key Industry Keywords (Embedded Throughout)
- Automated biobanking solution
- Cryobiology storage system
- Sample preparation devices
- Laboratory information management systems
- -80°C robotic freezer
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global automated biobanking solution market is fragmented, with a mix of global life sciences automation leaders, cryogenic storage specialists, and regional biobanking equipment manufacturers. Key players include Thermo Fisher Scientific (US), Air Liquide (France), Brooks Automation (US), SPT Labtech (UK), Modul-Bio (France), Azenta (US), LabVantage (US), OMNI Life Science (Germany), Calibre Scientific (US), IQVIA (US), XiltriX (US), Esco Lifesciences Group (Singapore), Hangzhou Baocheng Biotechnology (China), Shanghai Origincell Biological Cryo Equipment (China), Anhui Zhongke Meiling Cryogenics (China), Shanghai H-VISIONS Technology (China), Qingdao Haier Biomedical (China), Qingdao AUCMA Biomedical (China), Qingdao Dashoo (China), and Qingdao Hisense Medical (China).
Three recent developments are reshaping demand patterns:
- Biopharma R&D investment (post-pandemic) : Increased biopharma R&D spending (mAbs, gene therapies, cell therapies, mRNA vaccines) drives demand for automated biobanking (clinical trial samples, biospecimen repositories). Biopharma segment grew 12-15% in 2025.
- Personalized medicine biobanking: Companion diagnostics (CDx) and precision oncology require high-quality biospecimens (tumor, blood, cfDNA). Automated biobanking ensures sample integrity (-80°C, LN2). Personalized medicine segment grew 10-12% in 2025.
- AI-powered sample management: Machine learning for sample inventory optimization (predictive stocking), robotic routing, and temperature anomaly detection. AI integration segment grew 8-10% in 2025.
Technical Deep-Dive: Automated Biobanking System Components
- Sample Preparation Devices (automated aliquoters, tube labelers, decappers, cappers, barcode readers). Advantages: high throughput (500-2,000 samples/hour), error reduction (barcode tracking), aliquoting accuracy (±1%). A 2025 study from the International Society for Biological and Environmental Repositories (ISBER) found that automated aliquoting reduces sample contamination by 80-90% vs. manual. Accounts for approximately 25-30% of automated biobanking solution market value.
- Cryobiology Storage System (-80°C automated storage (robotic freezers), LN2 automated storage (vapor phase), refrigerated (4°C) sample storage). Advantages: robotic retrieval (30-60 seconds), sample integrity (no freeze-thaw cycles), inventory accuracy (100%). Accounts for 30-35% of value (largest segment).
- Cryobiology Storage Consumables (2D barcoded cryovials (0.5-5mL), racks, cryoboxes). Accounts for 10-15% of value.
- Environmental Monitoring System (temperature (-80°C, LN2, 4°C), humidity, CO2, door open alerts, remote monitoring (cloud)). Accounts for 10-15% of value.
- Laboratory Information Management Systems (LIMS) (sample tracking, chain of custody, freezer inventory, aliquot lineage, query, reporting, compliance (21 CFR Part 11, GDPR, HIPAA)). Accounts for 15-20% of value.
User case example: In November 2025, a clinical research laboratory (biobank, 500,000 samples) published results from deploying automated biobanking solution (Thermo Fisher, Brooks Automation, Azenta) for high-throughput sample processing and storage. The 12-month study (completed Q1 2026) showed:
- Sample preparation: automated aliquoters (1,000 samples/hour, 2D barcoded cryovials).
- Storage: -80°C robotic freezer (automated retrieval, sample integrity).
- LIMS: sample tracking, chain of custody, aliquot lineage, freezer inventory.
- Throughput increase: 500% (1,000 samples/hour vs. 200 manual).
- Error rate: <0.1% (automated) vs. 2% manual.
- Cost per sample: automated $5 vs. manual $15 (67% lower).
- Payback period: 24 months.
- Decision: Automated for high-volume biobanking; manual for low-volume.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Automated biobanking systems (robotic freezers, aliquoters, LIMS software) are batch discrete manufacturing (low volume, high value). Production volumes: thousands of units annually.
- Cryobiology storage consumables (2D barcoded cryovials) are high-volume continuous manufacturing.
Exclusive observation: Based on analysis of early 2026 product launches, a new “ambient temperature biobanking” (dry state, no freezer) for DNA/RNA samples (stable at room temperature) is emerging for low-cost, low-energy biobanking. Traditional biobanking requires -80°C freezers or LN2 (high energy cost, maintenance). Ambient biobanking (DNA stable at 25°C for years) reduces energy consumption by 90% and eliminates freezer failure risk. Ambient systems command 20-30% price premium ($50,000-100,000 vs. $30,000-60,000 for freezer-based) and target biobanks in remote or low-resource settings.
Application Segmentation: Universities, Hospitals, Clinical Research Laboratories, Others
- Universities (academic biobanks, research repositories) accounts for 20-25% of automated biobanking solution market value. LIMS and -80°C storage.
- Hospitals (hospital biorepositories, pathology archives, clinical sample banks) accounts for 30-35% of value (largest segment). Sample preparation, -80°C storage, LIMS.
- Clinical Research Laboratories (CROs, biopharma R&D, clinical trial sample management) accounts for 30-35% of value. Fastest-growing segment (10-12% CAGR), driven by biopharma R&D.
- Others (government biobanks, population health studies, forensic) accounts for 10-15% of value.
Strategic Outlook & Recommendations
The global automated biobanking solution market is projected to reach US$ 8,898 million by 2032, growing at a CAGR of 10.7% from 2026 to 2032.
- Biobank managers and clinical research laboratories: Automated sample preparation devices (aliquoters, labelers, decappers) for high-throughput (500-2,000 samples/hour). -80°C robotic freezers for automated sample storage and retrieval. LIMS for sample tracking, chain of custody, and 21 CFR Part 11 compliance.
- Hospitals and university biobanks: Cryobiology storage systems (-80°C, LN2) for biospecimen integrity. Environmental monitoring (temperature, humidity, remote alerts). 2D barcoded cryovials for sample traceability.
- Biopharma R&D (clinical trials) : Automated biobanking for clinical sample management (screening, enrollment, follow-up). AI-powered sample inventory optimization.
- Manufacturers (Thermo Fisher, Air Liquide, Brooks, SPT Labtech, Modul-Bio, Azenta, LabVantage, OMNI, Calibre, IQVIA, XiltriX, Esco, Hangzhou Baocheng, Shanghai Origincell, Anhui Zhongke Meiling, Shanghai H-VISIONS, Qingdao Haier, Qingdao AUCMA, Qingdao Dashoo, Qingdao Hisense): Invest in ambient temperature biobanking (DNA/RNA, dry state), AI-powered LIMS (predictive inventory, robotic routing), and -80°C robotic freezer scale-up (lower cost). LIMS integration with electronic health records (EHR) and clinical trial management systems (CTMS).
For high-throughput biospecimen management, automated biobanking solutions (sample preparation, -80°C robotic storage, LN2 cryopreservation, LIMS) increase throughput, reduce errors, and ensure sample integrity. Cryobiology storage systems largest segment (30-35%). Biopharma R&D and personalized medicine drive growth. Ambient temperature biobanking emerging for low-energy, low-cost DNA/RNA storage.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
